Neuraxis CMO receives 47,569 RSUs as equity pay

Neuraxis, Inc. reported that executive Adrian Miranda, its CMO and SVP of Science & Technology, acquired 47,569 restricted stock units (RSUs) on January 22, 2026.

Rhea-AI Filing Summary

Neuraxis, Inc. reported that executive Adrian Miranda, its CMO and SVP of Science & Technology, acquired 47,569 restricted stock units (RSUs) on January 22, 2026. These equity awards were granted as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan.

The RSUs vest in three equal annual installments over a three-year period, aligning Miranda’s compensation with longer-term company performance. After this grant, Miranda directly holds 47,569 derivative securities linked to Neuraxis common stock.

Insider Trade Summary

Grant/Award: 47,569 shares

Grant/Award 1 txn

Insider Miranda Adrian

Role CMO, SVP Science & Tech

Type	Security	Shares	Price	Value
Grant/Award	RSU	47,569	$4.63	$220K

Holdings After Transaction: RSU — 47,569 contracts (Direct)

Footnotes (1)

1. F1. These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity transaction did Neuraxis (NRXS) report for Adrian Miranda?

Neuraxis reported an RSU grant to executive Adrian Miranda. He received 47,569 restricted stock units as compensation, aligning part of his pay with Neuraxis stock performance under the company’s 2022 Omnibus Securities and Incentive Plan.

How many RSUs did Adrian Miranda receive from Neuraxis (NRXS) and at what reference price?

Adrian Miranda received 47,569 restricted stock units from Neuraxis. The Form 4 lists a reference price of $4.63 per unit, indicating the grant-date value used for reporting, though RSUs themselves are typically settled in shares upon vesting rather than purchased for cash.

What is the vesting schedule for Adrian Miranda’s Neuraxis (NRXS) RSU grant?

The RSUs vest in three equal annual installments over three years. This means one-third of the 47,569 units becomes eligible to settle into shares each year, encouraging longer-term retention and alignment with Neuraxis’ multi-year performance.

Under which equity plan were Adrian Miranda’s Neuraxis (NRXS) RSUs granted?

The RSUs were granted under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan. This plan, as amended, governs stock-based compensation awards such as restricted stock units for executives and other eligible participants.

Does this Neuraxis (NRXS) Form 4 show any stock sales by Adrian Miranda?

No, the Form 4 shows only an acquisition of RSUs. The single reported transaction uses code “A” for a grant, award, or other acquisition, and the summary shows zero sell or dispose transactions in this filing.

What is Adrian Miranda’s Neuraxis (NRXS) derivative holdings after this RSU grant?

After the reported grant, Adrian Miranda holds 47,569 derivative securities. These are restricted stock units tied to Neuraxis common stock, all held directly, reflecting his current RSU position following the January 22, 2026 award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miranda Adrian

(Last) (First) (Middle)

11611 N. MERIDIAN ST,

SUITE 330

(Street)

CARMEL IN 46032

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CMO, SVP Science & Tech

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
RSU	(1)	01/22/2026		A		47,569		(1)	(1)	Common Stock	47,569	$4.63	47,569	D

Explanation of Responses:

1. These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

	/s/ Adrian Miranda	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.